登录    
  
首页 > 期刊论文 > 论文摘要
EIF5A2基因在恶性肿瘤中的研究进展
         
Progress in EIF5A2 gene in malignant tumors

摘    要
真核翻译起始因子5A2(eukaryotic translation initiation factor 5A2,EIF5A2)是EIF家族中一种保守的小分子量酸性蛋白质。研究发现,EIF5A2在肺癌、乳腺癌和宫颈癌等多种恶性肿瘤中过表达。EIF5A2主要通过诱导上皮-间质转化(epithelial-mesenchymal transition,EMT)促进肿瘤的发生和发展。N1-甲脒基-1,7-二氨基庚烷(N1-guanyl-1,7-diaminohep-tane,GC7)、环吡司(ciclopirox,CPX)和细胞活素类等药物的联合治疗,可干扰EIF5A2的翻译后修饰,进而抑制EIF5A2的活性,有望成为临床用药的不错选择。研究表明,EIF5A2作为一种致癌基因,可能成为肿瘤诊断和治疗中有效的分子生物学标志。本文就近年来EIF5A2在恶性肿瘤中的研究进展进行综述。
标    签 肿瘤   真核细胞起始因子类   上皮-间质转化   Neoplasms   Eukaryotic initiation factors   Epithelial-mesenchymal transition  
 
Abstract
Eukaryotic translation initiation factor 5A2 (EIF5A2) is a small universally conserved acidic protein classified in the EIF family. It has been found that EIF5A2 is widely over-expressed in various carcinomas, such as lung cancer, breast cancer and cervical cancer. EIF5A2 mainly promotes the occurrence and development of carcinoma by inducing epithelial-mesenchymal transition. A combination therapy with N1-guanyl-1, 7-diaminohep-tane (GC7), ciclopirox (CPX) and cytokines pharmacological agents can inhibit the activity of EIF5A2 through interfering the process of hypusine post-translational modification, and it is expected to be a good choice for clinical medication. Studies have shown that EIF5A2, as a carcinogenic gene, may be an effective molecular biomarker in the diagnosis and treatment of cancer. This review summarizes the progress in EIF5A2 in carcinoma.

中图分类号 R730   DOI 10.3781/j.issn.1000-7431.2018.55.654

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 综述

基金项目

收稿日期 2017/9/21

修改稿日期 2017/11/14

网络出版日期

作者单位点击查看


引用该论文: ZHOU Wu,WANG Junjie. Progress in EIF5A2 gene in malignant tumors[J]. Tumor, 2018, 38(3): 270~277
周婺,王俊杰. EIF5A2基因在恶性肿瘤中的研究进展[J]. 肿瘤, 2018, 38(3): 270~277


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】KEMPER WM, BERRY KW, MERRICK WC. Purification and properties of rabbit reticulocyte protein synthesis initiation factors M2Bα and M2Bβ[J]. J Biol Chem, 1976, 251(18):5551-5557.
 
【2】JACKSON RJ, HELLEN CU, PESTOVA TV. The mechanism of eukaryotic translation initiation an d principles of its regulation.[J]. Nat Rev Mol Cell Biol, 2010, 11(2):113-127.
 
【3】CARAGLIA M, PARK MH, WOLFF EC, et al. eIF5A isoforms and cancer:two brothers for two functions?[J]. Amino Acids, 2013, 44(1):103-109.
 
【4】WANG FW, GUAN XY, XIE D. Roles of eukaryotic initiation factor 5A2 in human cancer[J]. I Int J Biol Sci, 2013, 9(10):1013-1020.
 
【5】MÉMIN E, HOQUE M, JAIN MR, et al. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation[J]. Cancer Res, 2014, 74(2):552-562.
 
【6】RAMASWAMY S, ROSS KN, LANDER ES, et al. A molecular signature of metastasis in primary solid tumors[J]. Nat Genet, 2003, 33(1):49-54.
 
【7】LI Y, FU L, LI JB, et al. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma[J]. Gastroenterology, 2014, 146(7):1701-1713.
 
【8】HUANG PY, ZENG TT, BAN X, et al. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy[J]. BMC Cancer, 2016, 16(1):1-9.
 
【9】HE LR, ZHAO HY, LI BK, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.[J]. Int J Cancer, 2011, 129(1):143-150.
 
【10】XU G, HUI Y, SHI X, et al. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2[J]. BMC Pulm Med, 2014, 14(1):174.
 
【11】LIU Y, DU F, CHEN W, et al. EIF5A2 is a novel chemoresistance gene in breast cancer[J]. Breast Cancer, 2015, 22(6):602-607.
 
【12】MENG QB, KANG WM, YU JC, et al. Overexpression of eukaryotic translation initiation factor 5A2(EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer[J]. PLos One, 2015, 10(3):e0119229.
 
【13】TANG DJ, DONG SS, MA NF, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma[J]. Hepatology, 2010, 51(4):1255-1263.
 
【14】WANG FW, CAI MY, MAI SJ, et al. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression[J]. Oncotarget, 2014, 5(16):6716-6733.
 
【15】ZHENG W, LI Z, NGUYEN AT, et al. Xmrk, Kras and Myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma[J]. PLoS One, 2014, 9(3):e91179.
 
【16】SHEK FH, FATIMA S, LEE NP. Implications of the use of eukaryotic translation initiation factor 5A (eIF5A) for prognosis and treatment of hepatocellular carcinoma[J]. Int J Hepatol, 2012, 2012(1):1-6.
 
【17】FUJIMURA K, WRIGHT T, STRNADEL J, et al. A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer[J]. Cancer Res, 2014, 74(22):6671-6681.
 
【18】WEI YX, CHEN G, YOU L, et al. Expression of eukaryotic translation initiation factor 5A2 in pancreatic adenocarcinoma and its correlation with the prognosis[J]. Zhongguo Yixue Kexueyuan Xuebao, 2013, 35(6):634-638.
 
【19】ZHU W, CAI MY, TONG ZT, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelialmesenchymaltransition.[J]. Gut, 2012, 61(4):562-575.
 
【20】SNEZHKINA AV, KRASNOV GS, LIPATOVA AV, et al. The dysregulation of polyamine metabolism in colorectal cancer is associated with overexpression of c-Myc and C/EBPβ rather than enterotoxigenic bacteroides fragilis infection[J]. Oxid Med Cell Longev, 2016, 2016(3):1-11.
 
【21】DENG B, WANG B, FANG J, et al. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2[J]. Sci Rep, 2016, 6:28301.
 
【22】WEI JH, CAO JZ, ZHANG D, et al. EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo[J]. Br J Cancer, 2014, 110(7):1767-1777.
 
【23】KHOSRAVI S, WONG RP, ARDEKANI GS, et al. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion[J]. Br J Cancer, 2014, 110(2):399-408.
 
【24】YANG S, GAO Y, WANG D, et al. Overexpression of Eukaryotic initiation factor 5A2 is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer[J]. Histopathology, 2016, 69(2):276-287.
 
【25】GUAN XY, FUNG JM, MA NF, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer[J]. Cancer Res, 2004, 64(12):4197-4200.
 
【26】ZIEGLER P, CHAHOUD T, WILHELM T, et al. Evaluation of deoxyhypusine synthase inhibitors targeting BCRABL positive leukemias[J]. Invest New Drugs, 2012, 30(6):2274-2283.
 
【27】PREUKSCHAS M, HAGEL C, SCHULTE A, et al. Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples:implications for new targeted therapies[J]. PLos One, 2012, 7(8):e43468.
 
【28】LIU RR, LV YS, TANG YX, et al. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species[J]. Oncotarget, 2016, 7(17):24348-24360.
 
【29】KHOSRAVI S, MARTINKA M, ZHOU Y, et al. Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma[J]. Oncol Lett, 2016, 12(5):3089-3100.
 
【30】YANG H, LI X, ZHOU Y, et al. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma[J]. Oncotarget, 2015, 6(28):26079-26089.
 
【31】ZHOU BF, WEI JH, CHEN ZH, et al. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples[J]. Oncotarget, 2016, 7(27):41703-41714.
 
【32】YANG J, YU H, SHEN M, et al. N1-guanyl-1, 7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation[J]. Cancer Sci, 2014, 105(2):219-227.
 
【33】MATHEWS MB, HERSHEY JW. The translation factor eIF5A and human cancer[J]. Biochim Biophys Acta, 2015, 1849(7):836-844.
 
【34】MURATA Y, MINAMI Y, IWAKAWA R, et al. ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma[J]. Cancer Sci, 2014, 105(4):490-497.
 
【35】LI L, LI W. Epithelial-mesenchymal transition in human cancer:comprehensive reprogramming of metabolism, epigenetics, and differentiation[J]. Pharmacol Ther, 2015, 150:33-46.
 
【36】GONZALEZ DM, MEDICI D. Signaling mechanisms of the epithelialmesenchymal transition[J]. Sci Signal, 2014, 7(344):re8.
 
【37】TIAN SB, YU JC, LIU YQ, et al. MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer[J]. World J Gastroenterol, 2015, 21(31):9337-9347.
 
【38】ZHANG W, FENG M, ZHENG G, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells[J]. Biochem Biophys Res Commun, 2012, 417(2):679-685.
 
【39】MARCHINI S, FRUSCIO R, CLIVIO L, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer[J]. Eur J Cancer, 2013, 49(2):520-530.
 
【40】ZHENG L, QI T, YANG D, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1[J]. PLoS One, 2013, 8(1):e55719.
 
【41】SONG YA, PARK YL, KIM KY, et al. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer[J]. Pathol Int, 2012, 62(2):127-136.
 
【42】YANG F, XUE X, BI J, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(3):437-445.
 
【43】ISOSAKA M, NⅡNUMA T, NOJIMA M, et al. A screen for epigenetically silenced microRNA Genes in gastrointestinal stromal tumors[J]. PLoS One, 2015, 10(7):e0133754.
 
【44】ZENDER L, VILLANUEVA A, TOVAR V, et al. Cancer gene discovery in hepatocellular carcinoma[J]. J Hepatol, 2010, 52(6):921-929.
 
【45】XU X, ZHOU Y, XIE C, et al. Genomewide screening reveals an EMT molecular network mediated by sonic hedgehog-Gli1 signaling in pancreatic cancer cells[J]. PLoS One, 2012, 7(8):e43119.
 
【46】BAO Y, LU Y, WANG X, et al. Eukaryotic translation initiation factor 5A2(eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition[J]. Cancer Cell Int, 2015, 15(1):1-7.
 
【47】CHEN W, LUO JH, HUA WF, et al. Overexpression of EIF-5A2 is an independent predictr of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(2):400-408.
 
【48】XU G, SHAO G, PAN Q, et al. MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2[J]. Am J Transl Res, 2017, 9(2):478-488.
 
【49】WANG X, JIANG R, CUI EH, et al. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation[J]. Eur Rev Med Pharmacol Sci, 2016, 20(7):1244-1250.
 
【50】CARAGLIA M, MARRA M, GIUBERTI G, et al. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells[J]. J Biochem, 2003, 133(6):757-765.
 
【51】LOU B, FAN J, WANG K, et al. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2(eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells[J]. Exp Cell Res, 2013, 319(17):2708-2717.
 
【52】FEI X, LIU Y, CHU H, et al. eIF5A2 is an alternative pathway for cell proliferation in cetuximabtreated epithelial hepatocellular carcinoma[J]. Am J Transl Res, 2016, 8(11):4670-4681.
 
【53】ROBEY RW, TO KK, POLGAR O, et al. ABCG2:a perspective[J]. Adv Drug Deliv Rev, 2009, 61(1):3-13.
 
相关信息
   标题 相关频次
 DZNep在肿瘤治疗中的研究进展
 4
 EB病毒潜伏膜蛋白1介导的上皮-间质转化增强鼻咽癌的转移潜能
 4
 叉头框Q1基因调控肿瘤发生和发展的研究进展
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 3
 外泌体在上皮-间质转化和肿瘤转移中作用的研究进展
 3
 CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用
 2
 MS4A基因家族与肿瘤的研究进展
 2
 Sam68基因过表达可促进乳腺癌MCF-7细胞发生上皮-间质转化
 2
 SEPT 9基因与恶性肿瘤关系的研究进展
 2
 TGM1基因过表达可抑制乳腺癌细胞的上皮-间质转化
 2
 125I内放疗联合热疗和化疗治疗中晚期肿瘤的临床观察
 2
 18F-FDG PET/CT在同时性多原发癌中的应用
 2
 1-磷酸鞘氨醇对恶性肿瘤生物学行为调控的研究进展
 2
 3株肺癌细胞中9个肿瘤相关基因的启动子甲基化状态和部分基因表达的相关性(英文)
 2
 AGE/RAGE参与结直肠癌细胞上皮-间质转化及肿瘤干性的调控
 2
 AMPK在肿瘤发生发展中的作用机制研究
 2
 Arresten抑制HUVEC细胞增殖和管腔形成的实验研究
 2
 Bcl-2与IP3R相互作用调控肿瘤细胞程序性死亡的研究进展
 2
 CD26/DPPⅣ与肿瘤相关的研究进展
 2
 CDK12与肿瘤相关性的研究进展
 2
 CIK细胞治疗恶性胸腔积液的临床研究
 2
 circRNAs作为生物标志物在肿瘤中的研究进展
 2
 Clusterin在恶性肿瘤治疗中的研究进展
 2
 CpG寡聚脱氧核苷酸在肿瘤免疫治疗中的应用进展
 2
 Eph及其配体Ephrin在肿瘤转移中的研究进展
 2
 EQ-5D-3L和FACT量表对北京癌症及癌前病变患者生活质量评估的信度和效度研究
 2
 GADD45在抗肿瘤治疗中的研究进展
 2
 Gli抑制剂GANT61抑制食管腺癌细胞发生上皮-间质转化
 2
 Hedgehog信号通路及其抑制物在抗肿瘤治疗中的研究进展
 2
 Hedgehog信号通路与肿瘤侵袭转移作用的研究进展
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2